BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11831908)

  • 1. Syntheses, calcium channel agonist-antagonist modulation activities, nitric oxide release, and voltage-clamp studies of 2-nitrooxyethyl 1,4-dihydro- 2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl)pyridine-5-carboxylate enantiomers.
    Shan R; Howlett SE; Knaus EE
    J Med Chem; 2002 Feb; 45(4):955-61. PubMed ID: 11831908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Syntheses, calcium channel agonist-antagonist modulation activities, and nitric oxide release studies of nitrooxyalkyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2,1,3-benzoxadiazol-4-yl)pyridine-5-carboxylate racemates, enantiomers, and diastereomers.
    Shan R; Velazquez C; Knaus EE
    J Med Chem; 2004 Jan; 47(1):254-61. PubMed ID: 14695839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Syntheses, calcium channel agonist-antagonist modulation activities, and voltage-clamp studies of isopropyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-pyridinylpyridine-5-carboxylate racemates and enantiomers.
    Vo D; Matowe WC; Ramesh M; Iqbal N; Wolowyk MW; Howlett SE; Knaus EE
    J Med Chem; 1995 Jul; 38(15):2851-9. PubMed ID: 7543577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and calcium channel-modulating effects of alkyl (or cycloalkyl) 1,4-dihydro-2,6-dimethyl-3-nitro-4-pyridyl-5-pyridinecarboxylate racemates and enantiomers.
    Ramesh M; Matowe WC; Akula MR; Vo D; Dagnino L; Li-Kwong-Ken MC; Wolowyk MW; Knaus EE
    J Med Chem; 1998 Feb; 41(4):509-14. PubMed ID: 9484501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, rotamer orientation, and calcium channel modulation activities of alkyl and 2-phenethyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(3- or 6-substituted-2-pyridyl)-5-pyridinecarboxylates.
    Iqbal N; Akula MR; Vo D; Matowe WC; McEwen CA; Wolowyk MW; Knaus EE
    J Med Chem; 1998 May; 41(11):1827-37. PubMed ID: 9599233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The design of (-)-(S)-2-nitrooxyethyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl) pyridine-5-carboxylate: a cardioselective positive inotropic derivative of Bay K 8644.
    Shan R; Knaus EE
    Bioorg Med Chem Lett; 1999 Sep; 9(17):2613-4. PubMed ID: 10498219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and voltage-clamp studies of methyl 1,4-dihydro-2, 6-dimethyl-5-nitro-4-(benzofurazanyl)pyridine-3-carboxylate racemates and enantiomers and of their benzofuroxanyl analogues.
    Visentin S; Amiel P; Fruttero R; Boschi D; Roussel C; Giusta L; Carbone E; Gasco A
    J Med Chem; 1999 Apr; 42(8):1422-7. PubMed ID: 10212128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and calcium channel modulating effects of isopropyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(thienyl)-5-pyridinecarboxylates.
    Miri R; Howlett SE; Knaus EE
    Arch Pharm (Weinheim); 1997 Oct; 330(9-10):290-4. PubMed ID: 9396387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enantioselective syntheses and calcium channel modulating effects of (+)- and (-)-3-isopropyl 5-(4-methylphenethyll) 1,4-dihydro-2,6-dimethyl-4-(2-pyridyl)-3,5-pyridinedicarboxylates.
    Iqbal N; Vo D; McEwen CA; Wolowyk MW; Knaus EE
    Chirality; 1994; 6(7):515-20. PubMed ID: 7986665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and calcium channel antagonist activities of 3-nitrooxyalkyl, 5-alkyl 1,4-dihydro-2,6-dimethyl-4-(1-methyl-5-nitro-2-imidazolyl)-3, 5-pyridinedicarboxylates.
    Miri R; Niknahad H; Vesal G; Shafiee A
    Farmaco; 2002 Feb; 57(2):123-8. PubMed ID: 11902654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and smooth muscle calcium channel antagonist effects of dialkyl 1,4-dihydro-2,6-dimethyl-4-aryl-3,5-pyridinedicarboxylates containing a nitrooxy or nitrophenyl moiety in the 3-alkyl ester substituent.
    Iqbal N; Knaus EE
    Arch Pharm (Weinheim); 1996 Jan; 329(1):23-6. PubMed ID: 8687280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and smooth muscle calcium channel antagonist effects of alkyl 1,4-dihydro-2,6-dimethyl-4-(pyridinyl)-5-[2-(4,5-dihydro- 4,4-dimethyloxazolin-2-yl)]-3-pyridinecarboxylates.
    Anana RD; Knaus EE
    Arch Pharm (Weinheim); 1996; 329(8-9):408-12. PubMed ID: 8915102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of 1,4-dihydropyridine calcium channel modulators having a diazen-1-ium-1,2-diolate nitric oxide donor moiety for the potential treatment of congestive heart failure.
    Velázquez C; Knaus EE
    Bioorg Med Chem; 2004 Jul; 12(14):3831-40. PubMed ID: 15210150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of pharmacological activities of 3, 5-dialkyl 1, 4-dihydro-2,6-dimethyl-4-nitroimidazole-3, 5-pyridine dicarboxylates.
    Miri R; Javidnia K; Kebriaie-Zadeh A; Niknahad H; Shaygani N; Semnanian S; Shafiee A
    Arch Pharm (Weinheim); 2003 Sep; 336(9):422-8. PubMed ID: 14528490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Syntheses and calcium channel antagonist activity of nifedipine analogues with methylsulfonylimidazolyl substituent.
    Shafiee A; Dehpour AR; Hadizadeh F; Azimi M
    Pharm Acta Helv; 1998 Jul; 73(2):75-9. PubMed ID: 9700935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric interactions at L-type calcium channels between FPL 64176 and the enantiomers of the dihydropyridine Bay K 8644.
    Usowicz MM; Gigg M; Jones LM; Cheung CW; Hartley SA
    J Pharmacol Exp Ther; 1995 Nov; 275(2):638-45. PubMed ID: 7473149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and smooth muscle calcium channel effects of dialkyl 1,4-dihydro-2,6-dimethyl-4-aryl-3,5-pyridinedicarboxylates containing a nitrone moiety in the 4-aryl substituent.
    Anana RD; Ng H; Howlett SE; Knaus EE
    Arch Pharm (Weinheim); 1997 Mar; 330(3):53-8. PubMed ID: 9167447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and calcium channel antagonist activity of dialkyl 1,4-dihydro-2,6-dimethyl-4-(pyridinyl)-3,5-pyridinedicarboxylates.
    Dagnino L; Li-Kwong-Ken MC; Wolowyk MW; Wynn H; Triggle CR; Knaus EE
    J Med Chem; 1986 Dec; 29(12):2524-9. PubMed ID: 3783612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative behavioral, neurochemical and pharmacological activities of dihydropyridine calcium channel activating drugs.
    O'Neill SK; McKay DW; Campbell N; Triggle CR; Crowley M; Bolger GT
    J Pharmacol Exp Ther; 1990 Jun; 253(3):905-12. PubMed ID: 1694243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Syntheses, calcium channel antagonist and anticonvulsant activities of substituted 1,4-dihydro-3,5-pyridinedicarboxylates containing various 3-alkyl ester substituents.
    Yiu SH; Knaus EE
    Arch Pharm (Weinheim); 1997; 330(1-2):35-43. PubMed ID: 9112813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.